A clinical-stage biotech company developing first-in-class targeted and immune-mediated therapeutics to fight cancer.

California-based Tempest Therapeutics is laying off 21 of its 26 full-time employees. The cuts come while the biotech is ...

Tempest Therapeutics is hunkering down to weather the storm that has engulfed its operations. | Tempest Therapeutics is ...

Tempest Therapeutics (TPST) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation, ODD, to TPST-1495, the ...

Shares of Tempest Therapeutics (TPST) ended higher on Wednesday amid a broader market rebound on the U.S. pausing tariffs and ...

The analyst expressed disappointment in the need for the downgrade, citing Tempest's possession of "striking, positive, randomized Phase 2 data with amezalpat in 1L HCC that could alter the current ...

Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer ...

Tempest aims to explore strategic alternatives for advancing pipeline studies that maximize shareholder value. Stock rises in ...

According to Tempest, its options include a partnership or licensing deal, as well as a merger or an acquisition.

Tempest Therapeutics is eyeing a strategic partner to continue amezalpat’s development amid ‘unavailable capital markets'.

Unable to secure additional financing amid a stormy market, Tempest Therapeutics has put a call out for partners as it seeks ...